Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...
GlobalData on MSN
HUTCHMED begins Phase III segment of metastatic PDAC treatment trial
HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III ...
Nanjing Delova Biotech Co., Ltd. ("Delova") today announced positive results from two pivotal Phase 3 clinical trials ...
Corvus Pharmaceuticals (CRVS) confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled Phase ...
This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...
Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients. This is an ASCO Meeting Abstract ...
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback